Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Radiofrequency ablation safe, effective for small renal masses

05 Oct 2018

Treatment with radiofrequency ablation (RFA) yields good long-term oncologic outcomes in patients with small renal masses but not in those with tumours >3 cm, a study has shown.

Researchers reviewed the medical records of 106 patients with renal tumours who underwent RFA. None of the patients had familial renal cell carcinoma syndromes. Outcomes examined included disease recurrence, disease-free survival (DFS), metastasis-free survival (MFS), cancer-specific survival (CSS) and overall survival (OS).

There were 112 tumours treated in total, with the mean size being 2.5 cm. Initial technical success was achieved in 97 percent of cases.

During a median follow-up of 79 months, a total of 10 recurrences occurred. Kaplan-Meier analysis revealed that DFS and CSS rates at 6 years were 89 percent and 96 percent, respectively. When analysis was stratified according to tumour size, DFS dropped to 68 percent for tumours >3 cm.

In the subgroup of patients with available 10-year follow-up data, actual rates of DFS, CSS and OS were 82 percent, 94 percent and 49 percent, respectively. None of the patients had recurrence after 5 years.

Currently, consensus recommendation states that smaller renal tumours should be treated with minimally invasive techniques to preserve renal function and avoid unnecessary surgical removal of the entire kidney. RFA, a recognized technique for treating small renal tumours, uses a high-frequency, alternating current within the targeted tissue to initiate ionic agitation generating frictional heat, which leads to cancer cell destruction when the temperatures exceed 60° C. [BJU Int 2014;113:416-428]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).